Petal Surgical, led by ex Intuitive and ex Verb operator Prash Chopra, has assembled surgical robotics royalty around a focused ultrasound platform. It hasn't yet shown the science.
Prash Chopra was in his twenties when his father died at 52 from surgical complications. The loss sits at the center of every interview he gives about the company he now leads, and it is the reason Petal Surgical exists at all.
But Chopra is not a surgeon. He is a medtech operator who spent years building surgical robots — first at Intuitive Surgical, the company that put the da Vinci system in operating rooms worldwide, and later at Verb Surgical, the now-shuttered Johnson & Johnson–Verily joint venture, according to his interview with Medical Design & Outsourcing. The company's own website describes him as "a former Intuitive Surgical innovator." The surgeons in the story are his co-founders, not him.
What Petal says it is building, in Chopra's telling, is bigger than another robot. The company is developing an incisionless surgical platform based on what it calls Millisecond Pulse Histotripsy — a form of focused therapeutic ultrasound that, in Petal's newsroom language, causes "Acoustic Liquefaction" of targeted tissue. No incision. No heat. No toxicity. The body, the company says, absorbs the debris naturally.
The mechanism sits in the same class of focused-ultrasound energy that HistoSonics uses for non-invasive tissue ablation, and that modality just got the strongest market validation of its life. HistoSonics was taken private in a reported $2.25 billion private-equity buyout shortly before Petal emerged from stealth in October 2025, per Medical Design & Outsourcing's reporting. That transaction is the unspoken reference point for every new entrant in the field.
Petal's roster is the part of the story that is hardest to argue with. Joining Chopra are co-founder surgeons Bowen Jiang and Nicholas Theodore, both of Johns Hopkins, according to the company's homepage. More consequentially, Dr. Frederic H. Moll — widely credited in trade press as a pioneer of surgical robotics for founding Intuitive Surgical and later Auris Health — has joined Petal's board of directors. Rony Abovitz, the founder of Mako Surgical, is a co-founding advisor.
Moll's board seat matters because it is the closest thing the focused-ultrasound field has to an institutional signal that the robotics establishment thinks Petal's bet is serious.
In 2025, Petal closed an oversubscribed Series A and came out of stealth. It has since announced an additional investment that, per the company's newsroom release, brought total funding past $25 million — a figure corroborated by lead seed investor TSV Capital. The add-on round was led by an unnamed "prominent high net worth investment firm" that the company has not publicly identified. Repeat participants include Draper Associates, Actions Capital (the firm formerly known as K50 Ventures), and Fong's Family Foundation.
Tim Draper, of Draper Associates, framed the bet in classic Draper terms: the company sits at the intersection of two megatrends and is being built by the people who know how to scale surgical platforms. Ryan Bloomer, founder of Actions Capital, told Petal's newsroom that his firm has now invested in three of Chopra's companies, calling Chopra "one of the most mission-driven founders I have ever backed." Both MassDevice and The Robot Report independently flagged the funding extension in their own coverage.
Petal is scheduled to present at LSI USA 2026, where it is likely to face a more technical audience than the trade press has offered so far.
None of this answers the question the technology will eventually have to answer. Petal has not, to date, published peer-reviewed preclinical data, an FDA submission, a regulatory pathway, or a human-trial readout. The Medical Design & Outsourcing interview is, in the public record, the most detailed technical description of the platform — and it is the founder describing his own platform. The "Acoustic Liquefaction" label is the company's term. The mechanism is plausible, the team is real, and the comparable transaction is large enough to make the bet non-frivolous.
But the company is asking readers, surgeons, and regulators to take on faith that focused ultrasound can be expanded from ablation — where HistoSonics proved the modality works — to a broader surgical standard of care where the clinical bar is higher. The star-studded team is the reason a $25-million-plus story gets reported at all. It is not, on its own, evidence that the scalpel is going away.
The grief that started the company is real. The team is unusually deep. The market just priced a focused-ultrasound company at $2.25 billion. Whether Petal can convert that into the incisionless surgery it has promised is the part of the story that has not yet been written — and Petal has not yet given the public the data to write it.